How to apply for your certificate
Applying to the RCGP for your CCT recommendation now takes three clicks, writes Fiona Erasmus. Read more
The plans, set out in a new cancer reform strategy, aim to guarantee an appointment with a specialist within just two weeks of referral for all patients with breast problems, not just those with suspected cancer.
Other plans include an expansion of the 62-day referral-to-treatment guarantee. Currently, only those referred as an urgent case by their GP are guaranteed treatment within 62 days.
The plans will allow specialists in hospitals and screening centres to fast track patients, putting them on a level with those referred urgently by their GP.
The DoH also recommends that cervical screening results should be made available within 14 days. At present, over half of patients have to wait six weeks or more for their results.
The age range for breast screening will be extended to years 47-73 over time, while the age of bowel screening will be extended from 70 up to 75 from 2010.
DoH cancer czar Professor Mike Richards said that the new extensions to the breast and bowel cancer screening programmes would drive up survival rates in England.
But RCGP spokeswoman Dr Sarah Jarvis questioned where the money and the staff would come from.
'Breast radiologists will be swamped with work,' she said.
Increasing the age for breast and bowel screening was no bad thing, but it was more important to complete the nationwide roll-out of the bowel-screening programme, added Dr Jarvis.
DoH proposals
Applying to the RCGP for your CCT recommendation now takes three clicks, writes Fiona Erasmus. Read more
Medicolegal advisor, Dr John Holden addresses some dilemmas on consent that may be faced by GPs. Read more
The WPBA should be seen as a developmental process, says the RCGP's Dr Jane Mamelok. Read more
Contributed by Mr Michael Booker, consultant obstetrician & gynaecologist, and fertility specialist ... Read more
Contributed by Mr David Scott-Coombes, consultant endocrine surgeon at the University Hospital of Wa... Read more
Contributed by Dr David Kernick, a GPSI in headache, based in Exeter. Read more
Pfizer has launched Toviaz (fesoterodine), a once-daily treatment for the symptoms of overactive bla... Read more
Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome po... Read more
The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line tr... Read more
Comments
Only registered users may comment. Log in now or register for a free account.